What's in Medecins Sans Frontieres, Netherlands's pipeline?

Medecins Sans Frontieres, Netherlands has 6 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Medecins Sans Frontieres, Netherlands's portfolio?

Top competitors by shared drug class: Armed Forces Research Institute of Medical Sciences, Thailand, Centers for Disease Control and Prevention, Centre for Global Health Research, Ghana, Charite University, Berlin, Germany, Epicentre.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/medecins-sans-frontieres-netherlands.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Medecins Sans Frontieres, Netherlands — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Medecins Sans Frontieres, Netherlands pipeline: 5 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
AM(FDC)	AM(FDC)	marketed			Neuroscience
AL	AL	marketed	xanthine oxidase inhibitor	xanthine oxidase	Rheumatology
AA(FDC)	AA(FDC)	marketed	Antimalarial combination	Plasmodium falciparum (multiple mechanisms: artemisinin-based ROS generation and quinoline-based heme polymerization inhibition)	Infectious Disease
AM(LT)	AM(LT)	marketed			Neuroscience
DP	DP	marketed	Betalactam antibiotic	transpeptidase	Infectious diseases

Therapeutic area mix

Neuroscience · 2
Infectious Disease · 1
Infectious diseases · 1
Rheumatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Armed Forces Research Institute of Medical Sciences, Thailand · 1 shared drug class
Centers for Disease Control and Prevention · 1 shared drug class
Centre for Global Health Research, Ghana · 1 shared drug class
Charite University, Berlin, Germany · 1 shared drug class
Epicentre · 1 shared drug class
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Albert Schweitzer Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Medecins Sans Frontieres, Netherlands:

Cite this brief

Drug Landscape (2026). Medecins Sans Frontieres, Netherlands — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medecins-sans-frontieres-netherlands. Accessed 2026-05-17.